标题
Safety concerns and risk management of multiple sclerosis therapies
作者
关键词
-
出版物
ACTA NEUROLOGICA SCANDINAVICA
Volume 136, Issue 3, Pages 168-186
出版商
Wiley
发表日期
2016-11-28
DOI
10.1111/ane.12712
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
- (2015) Luisa Klotz et al. BMC Neurology
- Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
- (2015) Aaron E. Miller CLINICAL THERAPEUTICS
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
- (2015) Athina Papadopoulou et al. Expert Opinion On Drug Safety
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide
- (2014) Emanuela Colombo et al. ANNALS OF NEUROLOGY
- New management algorithms in multiple sclerosis
- (2014) Per Soelberg Sorensen CURRENT OPINION IN NEUROLOGY
- Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis
- (2014) Melanie D Ward et al. Expert Opinion On Drug Safety
- Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
- (2014) Per Soelberg Sorensen et al. JOURNAL OF NEUROLOGY
- Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
- (2014) A. Gueguen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
- (2014) Marinella Clerico et al. JAMA Neurology
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
- (2013) L. Azzopardi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
- (2013) Tomas Olsson et al. Multiple Sclerosis Journal
- L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
- (2013) N. Schwab et al. NEUROLOGY
- BG-12 in Multiple Sclerosis
- (2013) Robert Fox et al. SEMINARS IN NEUROLOGY
- Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab
- (2012) B.K. Kleinschmidt-DeMasters et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
- (2012) Christian Confavreux et al. Multiple Sclerosis Journal
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
- (2012) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Severe relapses under fingolimod treatment prescribed after natalizumab
- (2012) D. Centonze et al. NEUROLOGY
- Lethal multiple sclerosis relapse after natalizumab withdrawal
- (2012) V. Rigau et al. NEUROLOGY
- Fingolimod-associated macular edema: Incidence, detection, and management
- (2012) N. Jain et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
- (2011) Jeffrey A. Cohen et al. ANNALS OF NEUROLOGY
- A Benign Form of Neuromyelitis Optica
- (2011) Nicolas Collongues ARCHIVES OF NEUROLOGY
- Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
- (2011) Malte C. Claussen et al. CLINICAL IMMUNOLOGY
- Principles of a new treatment algorithm in multiple sclerosis
- (2011) Hans-Peter Hartung et al. Expert Review of Neurotherapeutics
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
- (2011) Giancarlo Comi et al. LANCET NEUROLOGY
- Intrathecal effects of daclizumab treatment of multiple sclerosis
- (2011) B. Bielekova et al. NEUROLOGY
- Immune reconstitution inflammatory syndrome in natalizumab-associated PML
- (2011) I. L. Tan et al. NEUROLOGY
- Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
- (2011) V. Martinelli et al. NEUROLOGY
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
- (2011) M. Mehling et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
- (2010) Richard A. Rudick et al. ANNALS OF NEUROLOGY
- Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
- (2010) Alexandra Schröder et al. ARCHIVES OF NEUROLOGY
- Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
- (2010) Chris H Polman et al. LANCET NEUROLOGY
- Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
- (2010) J. J. Marriott et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD20-Targeted Therapy: The Next Generation of Antibodies
- (2010) Tom van Meerten et al. SEMINARS IN HEMATOLOGY
- Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
- (2009) Eamonn S. Molloy et al. ARTHRITIS AND RHEUMATISM
- Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
- (2009) R Ellis et al. Multiple Sclerosis Journal
- Mitoxantrone: benefits and risks in multiple sclerosis patients
- (2009) V. Martinelli et al. NEUROLOGICAL SCIENCES
- Mitoxantrone and cytotoxic drugs' mechanisms of action
- (2009) T. Vollmer et al. NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Gene expression analysis of interferon-β treatment in multiple sclerosis
- (2008) F Sellebjerg et al. Multiple Sclerosis Journal
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
- (2008) O. Stuve et al. NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search